Abstracts tagged "Sjögren’s syndrome"

Abstract Number: LB11 • ACR Convergence 2025
Efficacy and Safety of Telitacicept in Patients with Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Study
Dong Xu¹, Shangzhu Zhang¹, Lin Qiao¹, Li Zhang¹, Wenxiang Wang², Lin Li², Binghua Xiao², Jing Zhang², Qing Zuraw³, Jianmin Fang² and Xiaofeng Zeng¹, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China (People's Republic), ²RemeGen Co., Ltd., Rheumatology, Yantai, China (People's Republic), ³Vor Biopharma Inc., Boston
Background/Purpose: Sjögren's disease (SjD) is a chronic autoimmune disease whose pathogenesis is associated with aberrant activation of B-lymphocytes. Telitacicept, a novel fusion protein, dually targets and…
Abstract Number: 2449 • ACR Convergence 2025
Patient Characteristics, Treatment and Prognosis in Patients with Neuromyelitis OpticaSpectrum Disorder Coexisting with Systemic Lupus Erythematosus or Sjögren’s Syndrome: An Analysis Using Japanese Inpatient Database
Hiroshi Shiba¹, Mikio Nakajima², Kaito Nakamura³, Yusuke Sasabuchi⁴, Hiroyuki Ohbe⁵, Yuya Kimura⁶, Tadahiro Goto⁷, Hiroki Matsui⁸, Kiyohide Fushimi⁹ and Hideo Yasunaga⁵, ¹Suwa central hospital, Chino, Japan, ²Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, Hiroo, Tokyo, Japan, ³Department of Rheumatology, Dokkyo Medical University, Shimotsuga, Tochigi, Japan, ⁴Department of Real-world Evidence, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁵Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁶Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁷Department of Health Data Science, Graduate School of Data Science, Yokohama City University, Yokohama, Kanagawa, Japan, ⁸Department of Clinical Epidemiology and Health Economics, School of Public Health, Bunkyo-ku, Tokyo, Japan, ⁹Department of Health Policy and Informatics, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Neuromyelitis optica spectrum disorder (NMOSD) can coexist with systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). Due to overlapping clinical presentations and the rarity…
Abstract Number: 2292 • ACR Convergence 2025
Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren’s Disease Patients: Results From a Double-Blinded Placebo-Controlled Study
Sandra G Pasoto¹, Talita Ribeiro², Nadia Emi Aikawa³, Ana C Medeiros-Ribeiro¹, Bruno Borges², Andre Franco⁴, Henrique Silva², Eloisa Bonfa⁵ and Clovis Artur Silva⁶, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ⁵Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁶University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Immunosuppressed Sjögren’s disease (SjD) patients are at increased risk of herpes zoster (HZ). Despite this vulnerability, data on safety and immunogenicity of the recombinant…
Abstract Number: 1682 • ACR Convergence 2025
Sjögren’s Disease Salivary Gland Fibroblast Subsets are Proinflammatory and Aberrantly Promote Pain
Sara McCoy¹, Rachael Bogle², michele larsen³, Li Chen⁴, thomas pranzatelli⁵, Paola Perez⁶, john chiorini⁷, Alan Baer⁸, A. Darise Farris⁹, Christopher Lessard⁹, Astrid Rasmussen⁹, Caroline Shiboski¹⁰, Stephen Shiboski¹⁰, Alexander Mikesell³, Zachary Campbell³, Alex Tsoi², Johann Gudjonsson¹¹ and Blake M. Warner¹², ¹University of Wisconsin–Madison, Madison, WI, ²University of Michigan, Holland, OH, ³University of Wisconsin, Madison, ⁴University of Michigan, Ann Arbor, ⁵NIH, Bethesda, ⁶NIDCR, Bethesda, MD, ⁷NIH, bethesda, MD, ⁸Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰University of California San Francisco, San Francisco, CA, ¹¹University of Michigan, Ann Arbor, MI, ¹²National Institutes of Health, Bethesda, MD
Background/Purpose: Fibroblasts (fb) are increasingly recognized as dynamic signaling hubs in rheumatic disease, yet their contribution to Sjögren Disease (SjD) remains poorly defined. We dissect…
Abstract Number: 1393 • ACR Convergence 2025
Prevalence of Sjögren’s Disease in the United States – A Retrospective Cohort Study Among a Commercially Insured Population (2019-2023)
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune condition characterized by diverse clinical manifestations, which often complicates diagnosis and disease management1. Previous epidemiological estimates of…
Abstract Number: 1361 • ACR Convergence 2025
Efficacy of Telitacicept in the treatment of Connective tissue disease-associated interstitial lung disease: A Potential therapeutic option
Mingfang Sun¹, Xue Chen², Ying Zhou², Yanlong Yang², Fei Xiao² and huanzi dai², ¹Daping Hospital, chongqing, China (People's Republic), ²Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China., Chongqing, China (People's Republic)
Background/Purpose: Connective tissue disease-associated interstitial lung disease(CTD-ILD) represents a significant cause of mortality among patients. Presently, research on treatment options for CTD-ILD is limited, with…
Abstract Number: 0512 • ACR Convergence 2025
Dry Eye Disease Severity and Salivary Gland Biopsy in Patients with Primary Sjögren’s Syndrome
Karina Palomo-Arnaud¹, Janett C. Riega-Torres², Jose Martinez-Delgado³, Fernando Morales-Wong³, Jesus Mohamed-Hamsho³, Valeria Mata-Riega¹, Irma Cantu-Zapata¹, Luis Medina-Gomez¹, Miguel Betancourt-De la Torre¹, Aritze Chong-Amezcua¹, Dionicio A. Galarza-Delgado⁴ and Karim Mohamed-Noriega³, ¹Hospital Universitario "Dr. José Eleuterio González", Rheumatology, Monterrey, Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Ofthalmology, Monterrey, Nuevo León, Monterrey, Nuevo Leon, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film. This is commonly observed…
Abstract Number: 2398 • ACR Convergence 2025
Analytical performance of the HEp-2 substrate Diagnostic Kit for ANA as an initial step in the evaluation of a novel Fully Automated IFA Analyzer in a laboratory in England
Jason Sillitoe¹, Ewa Fiorentino-Rozek², Gerber Gomez³, Christian Fischer³ and Caroline Wilson¹, ¹North East Innovation Lab, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ²Clinical Affairs, AliveDx Suisse SA, Eysins, Vaud, Switzerland, ³Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Indirect immunofluorescence assay (IFA) on HEp-2 cells (HEp-2 IFA) remains a key tool in the diagnostic work-up of autoimmune connective tissue diseases (CTD). Traditionally…
Abstract Number: 2291 • ACR Convergence 2025
Correlation and Concordance Between the Oxford Grading Scale, Ocular Staining Score, and van BijsterveldScore in the diagnosis of Sjögren’s Disease
Alejandro Gómez Gómez¹, Eric Kirkegaard-Biosca², Sergio H. Martínez Mateu³, Iago Alvarez Saez⁴, Natalia Boix- Martí⁵, Antonio Julià¹, Jose Luis Andreu⁶ and Sara Marsal¹, ¹Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, ²Hospital Univetsitari Vall d'Hebron, Ophthalmology Department, Barcelona, Spain, ³IMIDomics, Barcelona, Spain, ⁴Hospital Univetsitari Vall d'Hebron, Maxilofacial Surgery Department, Barcelona, Spain, ⁵Hospital Univetsitari Vall d'Hebron, Rheumatology Department, Barcelona, Spain, ⁶Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Sjögren’s Disease (SjD) is a systemic autoimmune disorder marked by mucosal dryness and ocular surface damage. For diagnosis, the ACR-EULAR 2016 criteria require the…
Abstract Number: 1680 • ACR Convergence 2025
Major salivary gland ultrasonographic features of lymphoma and high lymphoproliferative risk lesions in Sjögren’s Disease: a systematic review
Alen Zabotti¹, Valeria Manfrè¹, Maria Teresa Rizzo¹, Alessia Nano¹, Garifallia Sakellariou² and Luca Quartuccio¹, ¹Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ²Department of Internal Medicine and Therapeutics, Università Di Pavia, Pavia, Italy; Istituti Clinici Scientifici Maugeri IRCCS Pavia, Pavia, Italy
Background/Purpose: Sjögren's disease (SjD) is burdened by significant lymphoproliferative risk. Up to date there is no established consensus on the salivary gland ultrasonographic (SGUS) features…
Abstract Number: 1392 • ACR Convergence 2025
Cancer Mortality in Sjogren’s Disease: Disproportionate Increase in Mortality from Cancers in Sjogren’s Disease Relative to All-Cancers
Margaret Essien and Ram Singh, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Sjögren's disease (SjD), an autoimmune condition with chronic inflammation in exocrine glands, is associated with increased risks of cancers. The impact of cancer on…
Abstract Number: 1223 • ACR Convergence 2025
Pain and Fibromyalgia Across Autoimmune and Inflammatory Diseases in the AMP AIM Cohort
Alexis Ogdie¹, Astrid Rasmussen², Dana Orange³, Michelle Petri⁴, Caroline Shiboski⁵, Rebecca Haberman⁶, Mala Masson⁷, Daniel Goldman⁴, Peter Izmirly⁸, Brooke Cohen⁹, Jennifer Seifert¹⁰, Jennifer Anolik¹¹, Wade DeJager¹², Alan Baer¹³, Jill Buyon¹⁴ and Yvonne Lee¹⁵, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³The Rockefeller University, New York, NY, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵University of California San Francisco, San Francisco, CA, ⁶NYU Langone Health, New York, NY, ⁷NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁸New York University Grossman School of Medicine, New York, NY, ⁹Yale Physician Associate Program, New Haven, CT, ¹⁰University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ¹¹University of Rochester Medical Center, Rochester, NY, ¹²Oklahoma Medical Research Foundation, Oklahoma City, ¹³Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁴NYU Grossman School of Medicine, New York, NY, ¹⁵Northwestern University, Chicago, IL
Background/Purpose: The Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) network seeks to understand the cellular and molecular interactions that lead to inflammation and…
Abstract Number: 0511 • ACR Convergence 2025
Submandibular Gland Ratio Stratifies Salivary Function and Reveals a Senescence Peak in Anti-SSA Positive Sjögren’s Syndrome
Chiao-Feng Cheng¹, Tseng-Cheng Chen², Min-Shu Hsieh³, TING-YUAN LAN⁴, Jui-Hung Kao⁵, Yu Heng Lin⁶, Mei-Fang Cheng⁷, Yi-Chieh Chen⁸, Hsiao-Sang Chu⁹, Yi-Min Huang¹⁰, Cheng-Hsun Lu¹¹, Ko-Jen Li¹¹, Chieh-Yu Shen¹ and Song-Chou Hsieh¹², ¹Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ²Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ³Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei ¹⁰⁰²²⁵, Taiwan, Taipei, Taiwan (Republic of China), ⁴National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ⁵Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Taipei, Taiwan (Republic of China), ⁶Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan, Taipei, Taiwan (Republic of China), ⁷Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ⁸Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ⁹Department of Ophthalmology, National Taiwan University Hospital, Taipei City, Taiwan., Taipei, Taiwan (Republic of China), ¹⁰Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ¹¹National Taiwan University Hospital, Taipei, Taiwan, ¹²National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: In primary Sjögren’s syndrome (pSS), the histologic focus score reflects immune infiltration but does not capture irreversible glandular damage. We evaluated a submandibular gland…
Abstract Number: 2397 • ACR Convergence 2025
Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
Guillaume Nardella¹, Gerber Gomez², Christian Fischer² and Claire Monat¹, ¹Inovie Labosud Provence, Specialized Autoimmunity Analyses, Marseille, France, ²Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Autoantibodies are key diagnostic markers in autoimmune connective tissue diseases (CTD). Conventional testing often requires multiple single-measurand assays, which can be labor-intensive and time-consuming.…
Abstract Number: 2290 • ACR Convergence 2025
Patterns and Predictors of Clinical Improvement in Patients with Sjögren’s Disease: A Longitudinal Analysis of ESSDAI and ESSPRI Improvements
Alejandro Gómez Gómez¹, Sergio H. Martínez Mateu², Jose Luis Tandaipan³, Monica Fernandez Castro⁴, Guillermo gonzalez⁵, Sheila Melchor-Díaz⁶, Miren Uriarte Ecenarro⁷, Raúl Menor Almagro⁸, Paloma Vela Casasempere⁹, Beatriz Paredes-Romero¹⁰, Judit Font-Urgelles¹¹, Paula Estrada-Alarcón¹², Sara Manrique-Arija¹³, Mª Angeles Blazquez Cañamero¹⁴, Clara Moriano¹⁵, Juan José Alegre-Sancho¹⁶, Marina Rodríguez López¹⁷, Marta López¹⁸, Gema Bonilla¹⁹, Rafaela Ortega-Castro²⁰, Sara Maria Rojas Herrera²¹, Ignacio Braña²², Lilian López-Núñez²³, Javier Narváez²⁴, Jose Rosas Gómez de Salazar²⁵, Ruben D. López-Sánchez²⁶, Carles Galisteo Veiga²⁷, Javier Martínez-Ferrin²⁸, Jose Javier Pérez Venegas²⁹, Guadalupe Manzano-Canabal³⁰, Cilia Peralta-Ginés³¹, Lara Sánchez Bilbao³², José Andrés Román Ivorra³³, Rafael Cáliz-Cáliz³⁴, Belén Serrano-Benavente³⁵, Sabela Fernández-Aguado³⁶, Natalia Boix- Martí³⁷, Eric Kirkegaard-Biosca³⁸, Iago Alvarez Saez³⁹, Ares Selles-Rius⁴⁰, Maribel Pérez⁴¹, Juan Cañete⁴², Sara Marsal¹ and Jose Luis Andreu⁴³, ¹Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, ²IMIDomics, Barcelona, Spain, ³Rheumatology. Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ⁵Hospital Universitario de A Coruña, A Coruña, Spain, ⁶Hospital Universitario ¹² de Octubre, Rheumatology, Madrid, Madrid, ⁷Hospital Universitario La Princesa, Madrid, Spain, ⁸Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ⁹Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁰Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ¹¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹²Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ¹³Hospital Regional Universitario Málaga, Malaga, Spain, ¹⁴Hospital Ramon y Cajal, Madrid, Spain, ¹⁵Hospital León, LEON, Castilla y Leon, Spain, ¹⁶Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁷Complejo Hospitalario Universitario de Santiago, Rheumatology, Santiago de Compostela., Santiago de Compostela, Spain, ¹⁸Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ¹⁹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ²⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ²¹Hospital de Mérida, Rheumatology, Badajoz, Badajoz, Spain, ²²Hospital Universitario Central de Asturias, Oviedo, Spain, ²³Hospital Son Llatzer, Rheumatology, Palma de Mallorca, Palma de Mallorca, Spain, ²⁴Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁵Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁶Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ²⁷Hospital Parc Taulí, Rheumatology, Sabadell, Sabadell, Spain, ²⁸Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Murcia, Spain, ²⁹Virgen Macarena University Hospital, Sevilla, Spain, Sevilla, Spain, ³⁰Hospital Virgen de la Concha (Zamora), Zamora, Spain, ³¹Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ³²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³³Hospital Universitari i Politècnic La Fe, Valencia, Spain, ³⁴Hospital Universitario Virgen de las Nieves, Rheumatology, Granada, Granada, Spain, ³⁵Hospital Gregorio Marañon, Madrid, Spain, ³⁶Hospital Universitario de Pontevedra, Pontevedra, Spain, ³⁷Hospital Univetsitari Vall d'Hebron, Rheumatology Department, Barcelona, Spain, ³⁸Hospital Univetsitari Vall d'Hebron, Ophthalmology Department, Barcelona, Spain, ³⁹Hospital Univetsitari Vall d'Hebron, Maxilofacial Surgery Department, Barcelona, Spain, ⁴⁰Rheumatology Research Group, Vall d'Hebron University Hospital, Barcelona, Spain, ⁴¹IMIDomics, Barcelona, Barcelona, Spain, ⁴²Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁴³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Assessing clinical improvements in Sjögren's Disease (SjD) is challenging. Our objective was to describe patterns of improvement in SjD using ESSDAI and ESSPRI indices…

1
2
3
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].